Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the alpha-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer Meeting Abstract
| Authors: | Schellens, J. H. M.; van Geel, R.; Bendell, J. C.; Spreafico, A.; Schuler, M.; Yoshino, T.; Delord, J. P.; Yamada, Y.; Lolkema, M. P.; Faris, J. E.; Eskens, F. A. L. M.; Sharma, S.; Yaeger, R.; Lenz, H. J.; Wainberg, Z. A.; Avsar, E.; Chatterjee, A.; Jaeger, S.; Demuth, T.; Tabemero, J. |
| Abstract Title: | Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the alpha-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer |
| Meeting Title: | 106th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 75 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 Apr 18-22 |
| Meeting Location: | Philadelphia, PA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-08-01 |
| Language: | English |
| ACCESSION: | WOS:000371597100032 |
| DOI: | 10.1158/1538-7445.am2015-ct136 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT136 -- 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 18-22, 2015 -- Philadelphia, PA -- Source: Wos |
